Friday, July 10, 2026
🇺🇸 FDA

pharma · Muscle-invasive bladder cancer · Unresectable intrahepatic cholangiocarcinoma

Ningbo Cancer Hospital

Ningbo Cancer Hospital clinical programs — 120 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
120
Drugs
183
Patents
0
All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Ningbo Cancer Hospital projects

120 ClinicalTrials.gov programs sponsored by Ningbo Cancer Hospital.

Ningbo Cancer Hospital has 120 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

120 programs

Clinical programs

Page 2 of 3

  1. -

    Ningbo Cancer Hospital

    Unresectable intrahepatic cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  2. 1537-LYMG

    Ningbo Cancer Hospital

    Advanced stage Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  3. 1634

    Ningbo Cancer Hospital

    Newly Diagnosed Medulloblastoma

    phase 2 small molecule active

    1 trial

  4. 20-27 PaTcH

    Ningbo Cancer Hospital

    Metastatic refractory Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  5. 2023-1-69-001

    Ningbo Cancer Hospital

    Hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  6. BAY 1841788 for Hormone Naive Prostate Cancer

    Ningbo Cancer Hospital

    Hormone Naive Prostate Cancer

    phase 2 small molecule active

    1 trial

  7. CTRIAL-IE 19-34

    Ningbo Cancer Hospital

    Newly diagnosed Multiple Myeloma

    phase 2 small molecule active

    1 trial

  8. Capecitabine Accord 500 mg film-coated tablets

    Ningbo Cancer Hospital

    Biliary tract cancer

    phase 2 small molecule active

    1 trial

  9. Cotellic 20 mg film-coated tablets, Ginisortamab

    Ningbo Cancer Hospital

    Metastatic pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  10. DS-8201a

    Ningbo Cancer Hospital

    Metastatic Breast Cancer HR+, HER2-

    phase 2 small molecule active

    1 trial

  11. EORTC 1612-MG

    Ningbo Cancer Hospital

    BRAF V600 mutation–positive unresectable or metastatic melanoma

    phase 2 small molecule active

    1 trial

  12. EORTC 1740-HNCG

    Ningbo Cancer Hospital

    Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  13. EORTC 2334-BTG

    Ningbo Cancer Hospital

    Recurrent Meningioma without local treatment options (Surgery or Radiotherapy)

    phase 2 small molecule active

    1 trial

  14. EORTC-1745-ETF-BCG

    Ningbo Cancer Hospital

    Localized ER+ breast cancer

    phase 2 small molecule active

    1 trial

  15. GEICAM/2014-12

    Ningbo Cancer Hospital

    Metastatic breast cancer

    phase 2 small molecule active

    1 trial

  16. GEICAM/2020-08

    Ningbo Cancer Hospital

    Non-resectable locally advanced or metastatic HER2-positive breast cancer

    phase 2 small molecule active

    1 trial

  17. GINECO- CE111b

    Ningbo Cancer Hospital

    Patients with a histilogically confirmed diagnosis of cervical squamous or adenosquamous carcinoma stage IB3 if N>=1 or II to IVA with any N stage according to FIGO 2018 and no evidence of metastatic disease (M0), without any prior anti-cancer treatment.

    phase 2 other active

    1 trial

  18. GINECO-EN203b

    Ningbo Cancer Hospital

    metastatic or recurrent endometrial or ovarian carcinosarcoma

    phase 2 small molecule active

    1 trial

  19. GINECO-OV243b

    Ningbo Cancer Hospital

    Patients with a confirmed diagnosis of ovarian small cell carcinoma.

    phase 2 small molecule active

    1 trial

  20. GINECO-OV244b

    Ningbo Cancer Hospital

    Platinum sensitive recurrent ovarian cancer

    phase 2 small molecule active

    1 trial

  21. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Muscle-invasive bladder cancer

    phase 2 small molecule active

    1 trial

  22. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Patients with locally advanced or metastatic solid tumours

    phase 2 small molecule active

    1 trial

  23. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Histologically confirmed frail Limited Disease Small Cell Lung Cancer (ECOG PS 2, ECOG PS 0-1 and older than 70 or did not receive a concomitant thoracic CRT because of comorbidities) previously untreated

    phase 2 small molecule active

    1 trial

  24. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Patients with metastatic breast cancer in 1st or 2nd line of chemotherapy

    phase 2 small molecule active

    1 trial

  25. IPILIMUMAB, NIVOLUMAB

    Ningbo Cancer Hospital

    type B3 thymoma and thymic carcinoma

    phase 2 small molecule active

    1 trial

  26. Iclusig 15 mg film-coated tablets

    Ningbo Cancer Hospital

    Chronic myelogenous leukemia

    phase 2 small molecule active

    1 trial

  27. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Cervical cancer

    phase 2 small molecule active

    1 trial

  28. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    MMRd/MSI-H stage II-III endometrial cancer

    phase 2 small molecule active

    1 trial

  29. JZP598

    Ningbo Cancer Hospital

    Adult Patients with HER2-IHC3+ selected solid cancers (endometrial, colorectal, head & neck or sarcoma) or HER2 mutant non-small cell lung cancer.

    phase 2 small molecule active

    1 trial

  30. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Ningbo Cancer Hospital

    Squamous cell carcinoma of vulva/vagina, Squamous cell carcinoma of the head and neck, Squamous cell carcinoma of penis, Squamous cell carcinoma of cervix, Squamous cell carcinoma of anus

    phase 2 small molecule active

    1 trial

  31. MOGAMULIZUMAB

    Ningbo Cancer Hospital

    Cutaneous T-cell lymphoma, a category of cancers of lymphocytes (a type of white blood cells) that primarily involve the skin, Cutaneous T-cell lymphoma (Mycosis Fungoides (MF)) and Sézary Syndrome (SS))

    phase 2 small molecule active

    1 trial

  32. NERATINIB, Sindiar 2 mg cápsulas duras

    Ningbo Cancer Hospital

    HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Breast Cancer.

    phase 2 small molecule active

    1 trial

  33. OPDIVO 10 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Early stage triple negative breast cancer

    phase 2 small molecule active

    1 trial

  34. PACLITAXEL AHCL /ml for Head and neck squamous cell carcinoma

    Ningbo Cancer Hospital

    Head and neck squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  35. Pemazyre 4.5 mg tablets

    Ningbo Cancer Hospital

    Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rearrangement or activating mutation, outside of the approved indications for any selective FGFR inhibitor in France

    phase 2 small molecule active

    1 trial

  36. Pluvicto 1 000 MBq/mL solution for injection/infusion

    Ningbo Cancer Hospital

    Clear Cell Renal Cell Carcinoma (ccRCC)

    phase 2 small molecule active

    1 trial

  37. Precision Cells

    Ningbo Cancer Hospital

    Precision Cell Immunotherapy

    phase 2 mab active

    1 trial

  38. SAKK 01/18

    Ningbo Cancer Hospital

    Stage IIA/B seminoma

    phase 2 small molecule active

    1 trial

  39. SAKK 08/23

    Ningbo Cancer Hospital

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  40. SAKK 16/18

    Ningbo Cancer Hospital

    Resectable, locally advanced non-small cell lung cancer (NSCLC, N2)

    phase 2 small molecule active

    1 trial

  41. SAKK 38/19

    Ningbo Cancer Hospital

    Disseminated large B-cell lymphoma

    phase 2 small molecule active

    1 trial

  42. Stivarga 40 mg film-coated tablets

    Ningbo Cancer Hospital

    Bone sarcoma

    phase 2 small molecule active

    1 trial

  43. TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN

    Ningbo Cancer Hospital

    Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.

    phase 2 small molecule active

    1 trial

  44. Tecentriq 1 200 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Muscle-invasive bladder cancer

    phase 2 small molecule active

    1 trial

  45. Tevimbra 100 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy.

    phase 2 small molecule active

    1 trial

  46. UC-0107/1810

    Ningbo Cancer Hospital

    BRAF(V600) mutation-positive melanoma with brain metastasis (MBM)

    phase 2 small molecule active

    1 trial

  47. UC-0110/1608

    Ningbo Cancer Hospital

    RAS and B-RAF wild-type metastatic colorectal cancer. RAS and B-RAF mutation will be determined using circulating cell-free DNA (ccfDNA) by IntPlex method

    phase 2 small molecule active

    1 trial

  48. UC-0110/1719

    Ningbo Cancer Hospital

    Localised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy, surgery, or radiotherapy

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Ningbo Cancer Hospital have?

120 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.